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Abstract 
Platinum complexes of the type [Pt(PL)(AL)]2+ where PL is a derivative of 1,10-phenanthroline and 
AL is cis-1,4-diaminocyclohexane (1,4-dach), have been synthesised and characterised by ultraviolet 
spectroscopy, elemental microanalysis, nuclear magnetic resonance and X-ray crystallography. The 
calf-thymus DNA binding affinity of these complexes was determined by isothermal titration 
calorimetry, revealing higher DNA affinity than their 1S,2S-diaminocyclohexane analogues. In vitro 
cytotoxicity was assessed in ten human cell lines, revealing unexpectedly low activity for the 1,4-
dach complexes. 
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1. Introduction 
Cancer is a globally prominent disease in western civilisation; it is the second-highest cause of 
death and has a lifetime diagnostic rate of 40-50% in Australia and the U.S.A.1, 2 Chemotherapy 
remains a widely-used treatment option, and large portion of treatment programs incorporate 
platinum drugs.3, 4 The globally approved drugs cisplatin, carboplatin and oxaliplatin are used in 
these programs; they kill cancerous cells by forming covalent adducts with their DNA.5 However, 
these drugs do have drawbacks; treatment results in toxic side effects such as nephrotoxicity, 
neurotoxicity and myelotoxicity, and there are many cancer types that they are not effective 
against.3, 6 These drawbacks have inspired the development of new platinum complexes (PCs) as 
chemotherapy agents; one example is the complex kiteplatin, which incorporates the ligand cis-1,4-
diaminocyclohexane (1,4-dach) in the form [Pt(1,4-dach)Cl2] (Figure 1).7 Kiteplatin is active 
against several cell lines that are resistant to cisplatin and oxaliplatin, and is at least as active as 
oxaliplatin against cells that are sensitive to current agents.8 Part of the reason for this may be that 
the 1,2-GG intrastrand adducts formed by kiteplatin inhibit DNA polymerase more than the adducts 
formed by cisplatin.9, 10 Research into kiteplatin has recently resurged, with many labs investigating 
the DNA binding activity of kiteplatin and synthesising platinum(IV) derivatives to improve 
cytotoxicity.11-17 
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Figure 1. Chemical structures of: 1,4-dach complexes 1-3 (left), 1,2-dach complexes 4-6 (right) and kiteplatin (middle). 
2 
 
Another promising class of PC with potent activity against cisplatin-resistant cells are polyaromatic 
PCs; these incorporate a polyaromatic ligand (PL), typically a 1,10-phenanthroline (phen) analogue, 
and a diamine ancillary ligand (AL) in the form [Pt(PL)(AL)]2+. The AL is usually a 1,2-
diaminocyclohexane (1,2-dach) analogue, either 1S, 2S (SS-dach) or 1R, 2R (RR-dach). These PCs 
are active against cisplatin-resistant cell lines,18 induce cell death in cancerous cells by a caspase-
independent mechanism,18-20 and bind to DNA through non-covalent intercalation.21 In particular, 
the lead complex [Pt(5,6-dimethyl-phen)(SS-dach)]Cl2 (56MESS, Figure 1) is up to 100 times more 
active than cisplatin in several cell lines, with nanomolar activity against L1210 murine leukaemia 
and Du145 prostate cancer cells.21 These polyaromatic PCs and kiteplatin each have demonstrated 
great potential as platinum drug candidates, due to their different cellular mechanisms and enhanced 
DNA repair inhibition, respectively, and due to their outperformance of cisplatin in several cell 
lines. These factors, in addition to kiteplatin’s higher activity than that of [Pt(1R,2R-dach)Cl2],8 
prompted the development of polyaromatic PCs incorporating 1,4-dach as an AL and phen, 5-
methyl-phen (5Mephen) and 5,6-dimethyl-phen (56Me2phen) as a PL (to produce complexes 1, 2 
and 3 respectively, Figure 1). Here we present a comparative study between complexes 1-3 and 
their 1,2-dach analogues (including PHENSS, complex 4, 5MESS, complex 5 and 56MESS, 
complex 6, Figure 1) in terms of calf-thymus DNA (CT-DNA) binding by isothermal titration 
calorimetry (ITC) and in vitro cytotoxicity in a panel of human cancer cell lines. 
2. Experimental Section 
2.1. Materials 
[Pt(1,4-dach)Cl2] (Kiteplatin) was synthesised as per reported previously.22 All purchased reagents 
were used as received and all solvents used were of analytical grade or higher. Silver chloride was 
obtained from BDH chemicals. Dimethyl formamide (DMF) was obtained from Merck. Phen, 
5Mephen, 56Me2phen, dipotassium hydrogen phosphate, potassium dihydrogen phosphate, sodium 
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chloride and CT-DNA were obtained from Sigma-Aldrich. Methanol was obtained from Chem 
Supply. Deuterium oxide was obtained from Cambridge Isotope Laboratories. 
2.2. Characterisation measurements 
NMR spectra were obtained using a 400 MHz Bruker Avance nuclear magnetic resonance 
spectrometer. All spectra were referenced internally to the deuterium oxide solvent and were 
obtained at room temperature. 1H spectra were obtained using a spectral width of 15 ppm and 128 
accumulations. 1H-195Pt heteronuclear multiple quantum correlation (HMQC) spectra were obtained 
using a spectral width of 2500 ppm and 256 data points for the 195Pt nucleus (F1 dimension), and a 
spectral width of 12 ppm and 2048 data points for the 1H nucleus (F2 dimension). The following 
abbreviations apply to spin multiplicity: s (singlet), bs (broad singlet), d (doublet), dd (doublet of 
doublets), pt (pseudotriplet), and m (multiplet). The chemical shift (parts per million) of each 
resonance were quoted as an approximate midpoint of its multiplicity. 
Electronic spectra were obtained on a Cary 1E spectrophotometer at a wavelength range of 200-350 
nm, using a 10 mm quartz cell. All spectra were recorded at room temperature and were 
automatically corrected for solvent baseline. Extinction coefficients were obtained through titration 
of 1 M solution of PC (10 μL) into 2400 μL of water. 
Positive-mode electrospray ionisation mass spectrometry (ESIMS) experiments were performed 
using a Waters TQ-MS triple quadrupole mass spectrometer fitted with an ESI source. Spectra were 
recorded in positive ion mode from analyte solutions injected (10 μL) into 0.1% trifluoroacetic acid 
in 50% aqueous acetonitrile flowing at 0.1 mL/min. A capillary voltage of 1.6 kV, cone voltage of 
25 V, desolvation temperature of 300 oC and desolvation flow rate (nitrogen) of 500 L/hr were 
employed. Spectra were collected over one minute with an m/z range of 50-1000. 
Microelemental analysis (C, H and N) was performed at the Chemical Analysis Facility, 
Department of Chemistry and Biomolecular Sciences, Macquarie University. An Elemental 
Analyser, Model PE2400 CHNS/O produced by PerkinElmer, USA, was used. 
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2.3. Synthesis of [Pt(PL)(1,4-dach)]2+ 
Using a modification of a previously established method,23 kiteplatin (~60 mg, 1 equiv) was 
dissolved in DMF (~4 mL), silver nitrate (2 equiv) was added and the solution stirred for 16 h at 
room temperature with light excluded. The resultant silver chloride precipitate was removed by 
centrifugation. PL (2 equiv) was added to the supernatant and the solution stirred for 16 h at 50 oC, 
again with light excluded. Another equivalent of PL was then added and the solution stirred again 
without light for 16 h at 50 oC. The DMF solution was removed through rotary evaporation, the 
crude product suspended in water and this suspension was filtered. The filtrate was then added to a 
separatory funnel and washed twice with dichloromethane (20 mL each). The aqueous layer was 
reduced to a volume of approx. 2.5 mL through rotary evaporation. Purification was achieved 
through a Sep-Pak® (20 cc, 2 g) column connected to a pump apparatus with UV detector (Bio-Rad, 
EM-1 Econo™ UV Monitor ). The column was activated with methanol (10 mL) and then flushed 
with water (~40 mL) until the absorbance equilibration. The crude product solution was then loaded 
onto the column and eluted with water at a flow rate of 1 mL/min. The product was collected, 
reduced in volume and the Sep-Pak® purification process repeated. Fractions were collected and 
their contents determined using 1H NMR. The fractions containing product were combined, reduced 
under pressure and lyophilised to produce a pale yellow solid. Yield and characterisation data are 
presented in Table 1, while NMR chemical shifts are presented in Table 2. 
Table 1. Summary of the characterisation data of complexes 1-3. 
  
 
Molecular Formula 
 ESI-MS (m/z) Microanalysis 
Calc.(Found) 
 
UV / λmax (nm) 
(ε/mol-1.dm3.cm-1)  
× 102 
 Yield [M-H]+ 
Calc.(Found) No (%) C H N 
1 [Pt(phen)(1,4-dach)](NO3)2·0.25H2O 70 488.2 (487.8) 34.98 
(34.84) 
3.67 
(3.44) 
13.60 
(13.53) 
278 (280), 226 (345) 
2 [Pt(5Mephen)(1,4-dach)](NO3)2·1.5H2O 62 502.2 (501.9) 34.86 
(34.96) 
4.16 
(3.76) 
12.84 
(12.96) 
281 (330), 229 (405) 
3 [Pt(56Me2phen)(1,4-dach)](NO3)2·1.5H2O 71 516.2 (515.8) 35.93 
(35.91) 
4.37 
(3.97) 
12.57 
(12.59) 
285 (340), 231 (450) 
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Table 2. Summary of the proton and platinum NMR chemical shifts (ppm) of complexes 1-3 and 1ʹ-3ʹ in D2O. 
Label 1 2 3 
H4 8.87 (2H, d, J = 8.2 Hz) 8.73 (1H, d, J = 8.3 Hz) 8.86 (2H, d, J = 8.6 Hz) 
H7 - 8.94 (1H, d, J = 8.5 Hz) - 
H2 8.72 (2H, d, J = 5.5 Hz) 8.63 (1H, d, J = 5.6 Hz) 8.61 (2H, d, J = 5.4 Hz) 
H9 - 8.70 (1H, d, J = 5.6 Hz) - 
H5 8.11 (2H, s) 7.86 (1H, s) - 
H3 8.04 (2H, dd, J = 8.6, 5.6 Hz) 7.99 (1H, dd, J = 8.5, 5.5 Hz) 8.0 (2H, dd, J = 8.8, 5.5 Hz) 
H8 - 8.06 (1H, dd, J = 8.5, 5.5 Hz) - 
CH3 - 2.78 (3H, s) 2.56 (6H, s) 
H1ʹ 3.65 (2H, pt, 3JPt-H = 87.0 Hz) 3.65 (2H, pt, 3JPt-H = 84.1 Hz)  3.67 (2H, pt, 3JPt-H = 76.8 Hz) 
HAʹ 1.90 (4H, m) 1.90 (4H, m) 1.91 (4H, m) 
HAʹ 1.79 (4H, m) 1.78 (4H, m) 1.79 (4H, m) 
1H/195Pt 8.83, 2760 8.82, 2690 8.83, 2700 
2.4. X-ray crystallography 
Single crystals of complex 1 were obtained by dissolving small amounts of sample in hot water and 
allowing the solution to cool to room temperature. Single crystal data for 1 was collected on the 
MX1 beamline at the Australian Synchrotron using Si<111> monochromated synchrotron X-ray 
radiation (λ = 0.71074). Data collection was performed at 100(2) K using BlueIce software24 and 
corrected for polarisation and Lorentz effects using XDS software.25 The absorption correction was 
then applied to the data using SADABS.26 The structure was solved with direct methods using 
SHELXT27, 28 and full-matrix least-squares refinement was performed using SHELXL-201427, 29 via 
the Olex2 interface.30 Two diffractions affected by beam stops were removed in the final structure 
refinement. All non-hydrogen atoms with occupancies over 0.5 were located from the electron 
density map and were refined anisotropically. The disordered lattice water molecule was modelled 
and refined isotropically without added hydrogen atoms, causing a B-level alert in the checkCIF. 
Hydrogen atoms bound to carbon and nitrogen were added in ideal positions and refined using a 
riding model. Crystallographic refinement parameters are summarised in Table 3. Supplementary 
crystallographic data for 1 can be found under CCDC 1583091. This data can be obtained free of 
charge at http://www.ccdc.cam.ac.uk/conts/retrieving.html, or from the Cambridge Crystallographic 
Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: (+44) 1223-336-033; or e-mail: 
deposit@ccdc.cam.ac.uk. 
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Table 3. Crystallographic data and structure refinement details for complex 1. 
Parameters Values 
Empirical formula C18H22N6O7.25Pt 
Formula weight 633.50 
Temperature/K 100(2) 
Crystal system monoclinic 
Space group C2/c 
a/Å 13.864(3) 
b/Å 25.762(5) 
c/Å 6.5990(13) 
β/o 110.57(3) 
Volume/Å3 2206.7(9) 
Z 4 
ρcalc /mg mm-3 1.907 
µ/mm-1 6.412 
F(000) 1232 
Crystal size/mm 0.12; 0.03; 0.03 
2Θ range for data collection/° 1.581 to 27.499° 
Index ranges -18 ≤ h ≤ 18, -33 ≤ k ≤ 33, -8 ≤ l ≤ 8 
Reflections collected 17054 
Independent reflections 2471 [Rint = 0.0419, Rsigma = 0.0211] 
Data/restraints/parameters 2469/0/152 
Goodness-of-fit on F2 1.065 
Final R indexes [I>=2σ (I)] R1 = 0.0380, wR2 = 0.1066 
Final R indexes [all data] R1 = 0.0384, wR2 = 0.1070 
Largest diff. peak/hole / e Å-3 1.63/-2.24 
2.5. Isothermal titration calorimetry – DNA Binding 
CT-DNA binding was assessed using a MicroCal ITC 200 calorimeter operating at 37 oC. Each 
platinum complex (564-750 μM) was titrated into a solution of CT-DNA (160 μM) in 
K2HPO4/KH2PO4 (10 mM, pH 7.0) and NaCl (50 mM) buffer. For a baseline, each PC was titrated 
into buffer alone, and this trace was subtracted from the PC-DNA binding trace. The titration 
program consisted of one 0.4 μL addition followed by 18 titrations of 2 μL, with a spacing of 180 s, 
reference power of 6 μcal/s and stirring speed of 750 rpm. Data was analysed using Origin 7.0 
(MicroCal version) using 200 iterations of a one-site binding model using the following equations. 
Experiments were performed in duplicate for each PC. 
𝜟𝜟𝜟𝜟 = −𝑹𝑹𝑹𝑹 𝐥𝐥𝐥𝐥𝑲𝑲 
𝜟𝜟𝜟𝜟 = 𝜟𝜟𝜟𝜟 − 𝜟𝜟𝜟𝜟
𝑹𝑹
  
7 
 
2.5. In vitro cytotoxicity 
Cytotoxicity assays were performed at the Calvary Mater Newcastle Hospital, Waratah, NSW, 
Australia. The cell lines tested were HT29 colon carcinoma, U87 glioblastoma, MCF-7 breast 
cancer, A2780 ovarian cancer, H460 lung cancer, A431 skin cancer, Du145 prostate cancer, BE2-C 
neuroblastoma, SJ-G2 glioblastoma, MIA pancreas cancer, and the non-tumour derived MCF10A 
breast line. All test agents were prepared as 30 mM stock solutions in water and stored at -20 ºC. 
All cell lines were cultured in a humidified atmosphere 5% CO2 at 37 ºC. The cancer cell lines were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) (Trace Biosciences, Australia) 
supplemented with 10% foetal bovine serum, 10 mM sodium bicarbonate penicillin (100 IU/mL), 
streptomycin (100 µg/mL), and glutamine (4 mM). The non-cancer MCF10A cell line was cultured 
in DMEM:F12 (1:1) cell culture media, 5% heat inactivated horse serum, supplemented with 
penicillin (50 IU/mL), streptomycin (50 µg/mL), 20mM Hepes, L-glutamine (2 mM), epidermal 
growth factor (20 ng/mL), hydrocortisone (500 ng/mL), cholera toxin (100 ng/mL), and insulin (10 
ug/mL).Cytotoxicity was determined by plating cells in duplicate in 100 mL medium at a density of 
2,500–4,000 cells per well in 96 well plates.  On day 0, (24 h after plating) when the cells were in 
logarithmic growth, 100 µL medium with or without the test agent was added to each well.  After 
72 h drug exposure growth inhibitory effects were evaluated using the MTT (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) assay and absorbance read at 540 nm.  An 
eight point dose response curve was produced from which the IC50 value was calculated, 
representing the drug concentration at which cell growth was inhibited by 50% based on the 
difference between the optical density values on day 0 and those at the end of drug exposure.  
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3. Results and Discussion 
3.1. Synthesis and characterisation 
Synthesis of complexes 1-3 could not be achieved through the typical reflux used for complexes of 
this type.31 NMR experiments suggested that much of the 1,4-dach was detached from the platinum 
centre, with only minor amounts of the final product formed. Instead, a gentler synthesis was 
undertaken to keep the 1,4-dach ligand coordinated. The addition of silver nitrate in DMF resulted 
in the conversion of [Pt(1,4-dach)Cl2] to the intermediate [Pt(1,4-dach)(DMF)2](NO3)2; the leaving 
groups of this product are more labile, allowing the reaction with phen derivatives to take place at 
50 oC rather than 100 oC. The phen addition was slow and incomplete with only one equivalent, and 
so two equivalents were used instead, with a third added the next day to ensure that as much of the 
product formed as possible. Scheme 1 summarises the synthesis process.  
2+
2+
2+
ClCl
Pt
NH2H2N
NN
R1 R2
Pt
NH2H2N
Pt
NH2H2N
DMF, 50 oC, 
dark, 72 h
O
N
O
N
DMF, RT, 
dark, 24 h
AgNO3 
2 equiv
PL
2 + 1 equiv
70%
NO3
NO3
NO3
NO3
 
Scheme 1. General synthesis of complexes 1-3. R1 and R2 are either H, CH3, or a mixture of the two. 
The filtering and DCM washes removed most of the excess phen, while the column purification 
removed the rest. During Sep-Pak® purifications in our previous work, the [Pt(1,2-dach)Cl2] 
intermediate typically eluted before the final product, with minor overlap of elution profiles. Here, 
the elution profile of the [Pt(1,4-dach)(DMF)2](NO3)2 intermediate overlapped with the product to a 
much greater extent. To maximise separation, the flow rate was set to 1 mL min-1, which was the 
lowest speed achievable without allowing diffusion to occur in the column. Even so, it typically 
took two runs through the column to separate most of the product from impurities. The gentler 
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reaction conditions and difficult separation are thought to be the reasons for the relatively low 
yields of ~70% compared to the typical yields of 80-85% of similar complexes.32, 33 The identity 
and purity of these complexes was confirmed through NMR spectra, mass spectra and elemental 
analysis. The electronic transitions in the UV spectra (Section S1) of 1-3 were comparable with 
those of similar phen platinum(II) analogues;33 the presence of methyl substituents on the 
phenanthroline resulted in a red-shift of each peak and the appearance of a shoulder in the peak at 
approx. 280 nm. 
3.2. NMR spectral assignment 
Characterisation of all complexes was achieved using 1H NMR and 1H-195Pt heteronuclear multiple 
quantum correlation (HMQC) NMR. The NMR spectra of complex 3 are shown as an example 
(Figures 2 and 3). For all complexes, the aromatic region signals of the phen derivatives exhibited 
the expected chemical shifts and multiplicities as per previous studies.33 In the aliphatic region, the 
1,4-dach signals were similar to that of kiteplatin; the H1ʹ proton presented a pseudo triplet due to 
platinum satellites at 3.67 ppm, and the multiplets corresponding to the other aliphatic protons 
(HAʹ) were present from approx. 1.95-1.75 ppm. The amine protons were not present due to 
exchange with D2O. To confirm the coordination of each ligand to the platinum centre, the 1H-195Pt 
NMR spectra of all complexes were obtained. These spectra demonstrated a series of proton 
correlations with a platinum resonance at approx. -2700 ppm. For example, the 1H-195Pt NMR 
spectrum of complex 3 (Figure 3) revealed a correlation between the phen proton H2 and Pt at 8.72 
ppm, as well as between the 1,4-dach proton H1ʹ and Pt at 3.86 and 3.67 ppm. The Pt chemical 
shifts of 1-3 were slightly higher than those reported for phen complexes of 1,2-dach (approx. -2800 
ppm).34 This kind of platinum peak difference was observed for complexes of 1,2-
diaminocyclopentane (approx. -2550 ppm), which was attributed to the ring strain of the pentane.33 
This suggests that a similar phenomenon has occurred here with complexes 1-3, although to a lesser 
extent, and demonstrates the sensitivity of the platinum nucleus to changes in environment.35 
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 Figure 2. 1H NMR spectrum of complex 3 in D2O, showing proton assignment. Inset: the structure of 1, showing proton 
NMR number assignment. Amine protons are not present due to D2O exchange. 
 
Figure 3. The 1H-195Pt HMQC spectrum of complex 3 in D2O, showing cross peak assignment of the platinum centre 
and proton resonances. 
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3.3. X-ray crystal structure of complex 1 
The crystal data and structural refinement details are summarised in Table 3 and selected bond 
lengths, angles and torsion angles are shown in Table 4. The asymmetric unit of 1 contains a half 
molecule and the full structure is generated by a two-fold symmetry expansion. The complex 
consists of a PtN4 coordination sphere with a square-planar coordination geometry for the platinum 
metal centre (Figure 4). The bond lengths and angles related to the phen ligand and platinum are 
consistent with the previously published polyaromatic PCs.32, 33 The 1,4-dach ligand adopted a 
twist-boat conformation similar to that seen in previous 1,4-dach complexes,7, 15, 36 with a N2-Pt1-
N2 bond angle of 96.3(3)° and Pt1-N2-C7 angle of 125.6(4)°. The N-Pt-N angle is 
approximately 13° larger than that of previous 1,2-dach complexes that adopt a chair 
conformation.32, 33 Relative to complexes of 1,2-dach, the large bite angle of the coordinated 1,4-
dach ligand appears to have had no effect on the conformation of the opposing phen ligand. 
Adjacent phen ligands stack along the c axis, with carbon-carbon distances between 3.4-3.5 Å (Fig. 
4B). This correlates with π-π interactions.37 
 
Figure 4. Crystal structure of complex 1: An ellipsoidal plot (probability 50%) showing the atom numbering system 
(A) and stacking views from a side (B) and top-down (C). Colour code: Pt in purple, N in blue, C in grey and H in 
white. Nitrate counter-ions and lattice water molecules have been omitted for clarity. Selected bond lengths (Å): Pt1-
N1: 2.062(4), Pt1-N2: 2.072(4). Selected bond angles and torsion angles (°): N1-Pt1-N1: 81.7(2), N1-Pt1-N2: 
172.6(2), N2-Pt1-N2: 96.3(3), Pt1-N2-C7: 125.6(4), N1-C1-C1-N1: 0.7(8). 
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3.4. DNA binding studies 
The DNA binding of 1-3 was assessed to determine if there were any differences in affinity between 
the 1,4-dach complexes and those of S,S-dach (complexes 4-6). 5a, the nitrate salt of 5, was also 
tested to determine if the counter-ion had any effect. The thermodynamic parameters of each PC-
DNA interaction are summarised in Table 4, and the ITC trace of 3 is shown as an example (Figure 
5). Similar to previous experiments with 6,21 the binding of 1-3 with CT-DNA resulted in two peaks 
per titration rather than one, again suggesting that the binding was biphasic in nature. All binding 
was spontaneous, with negative changes in enthalpy and overall negative Gibbs free energy. The 
affinity of 5 was found to be slightly higher than that of 5a, which suggests that the presence of 
chloride counter-ions results in a slightly higher DNA affinity than complexes with nitrates. The 
ΔH and TΔS differences between 5 and 5a are too small to make any meaningful statement 
regarding thermodynamics, and so reason behind this difference in affinity is unknown. Counter-
ions were recently shown to effective DNA affinity to a larger extent for a pair of cobalt 
complexes,38 so this phenomenon is not unusual. Regardless, the affinity of complexes 1-3 were 
found to be ~0.7-2.4 × 105 M-1 higher than that of their SS-dach counterparts (Figure 6). This 
suggests that the 1,4-dach ligand does impact the DNA binding of these PCs to some extent, and 
minor changes in DNA binding behaviour based upon AL have been observed previously.23 The PL 
trend of 56Me2phen > 5Mephen > phen was observed for 1-3, although the affinity of 2 relative to 3 
was slightly higher than expected. 
Table 4. Isothermal titration calorimetry data for complexes 1-6 and 5ꞌ. 
No Complex 10-5 K [M-1] N ΔH [kcal mol-1] TΔS [kcal mol-1] ΔG [kcal mol-1] 
1a PHENK 2.87 ± 0.04 0.257 ± 0.006 -2.5 ± 0.1 5.2 ± 0.1 -7.7 ± 0.1 
2a 5KITE 6.2 ± 0.4 0.31 ± 0.01 -3.8 ± 0.1 4.2 ± 0.1 -8.1 ± 0.2 
3a 56KITE 7.7 ± 0.8 0.325 ± 0.005 -6.0 ± 0.1 2.1 ± 0.2 -8.1 ± 0.2 
4b,c PHENSS 2.0 ± 0.3 0.27 ± 0.01 -3.7 ± 0.1 3.9 ± 0.4 -7.5 ± 0.7 
5b 5MESS 3.8 ± 0.2 0.271 ± 0.004 -3.5 ± 0.2 4.3 ± 0.1 -7.8 ± 0.2 
6b,c 56MESS 5.7 ± 0.5 0.33 ± 0.01 -5.6 ± 0.1 2.6 ± 0.2 -8.2 ± 0.6 
5aa 5MESS 3.2 ± 0.3 0.265 ± 0.004 -3.4 ± 0.1 4.3 ± 0.1 -7.7 ± 0.2 
a – tested as a nitrate salt, b – tested as a chloride salt, c – values from reference 21. 
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 Figure 5. ITC trace and binding curve of the titration of complex 3 (564 μM) into CT-DNA (160 μM). Fits were 
obtained using a one-site binding model. 
 
Figure 6. Comparison of the DNA binding constants of 1-3 (1,4-dach, blue) and 4-6 (SS-dach, green). 
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3.5. In vitro cytotoxicity 
The in vitro cytotoxicity of complexes 1-3 was assessed using the MTT assay in ten human cancer 
cell lines and one “normal” cell line. These data were compared with those of 4-6 and their R,R 
isomers (4ꞌ-6ꞌ), as well as those of cisplatin, carboplatin and oxaliplatin (Table 5). 5 and 5ꞌ had not 
previously been tested in this panel of cell lines; the activity of 5 relative to 6 is consistent with 
previous cytotoxicity studies in that 6 is more active yet 5 is still very cytotoxic.23 In most cell lines 
6 is approx. 1.5-3 times more active than 5, although 5 is more active than 6 against HT29 cells 
with an IC50 of 0.02 ± 0.01 μM. In contrast, 6 is approx. 15-60 times more active than 6ꞌ in most 
cell lines; this reaffirms that while both the presence of methyl groups on the PL and SS-dach as an 
AL each improve cytotoxicity, the latter makes much more of a difference. The activity of 1-3 was 
lower than anticipated, with 1 being inactive in most lines and equivalent to cisplatin against HT29 
cells. Complex 2 demonstrated notable activity in HT29 cells only, and was relatively inactive in 
most other cell lines. Complex 3 was more active than cisplatin in MIA cells, equivalent to cisplatin 
in A431 cells, and was comparable to 4ꞌ against HT29, MCF-7, A2780 and BE2-C lines (Figure 7). 
The low cytotoxicity of 1-3 despite their high DNA affinity shows that DNA is not likely their 
target, or that the complexes are unable to reach nuclear DNA. It is clear that the improvement in 
cytotoxicity that 1,4-dach provides for kiteplatin over [Pt(RR-dach)Cl2] is not transferrable to 
[Pt(PL)(AL)]2+ complexes. Considering that 56MESS is known to disrupt cellular machinery 
through several methods unrelated to DNA,18, 20, 39 and that the proposed mechanism of action of 
kiteplatin is the formation of DNA adducts that are harder to remove than those of cisplatin,10 it is 
possible that the benefits of 1,4-dach over 1,2-dach only apply to the formation of covalent 
platinum-DNA adducts, which are not relevant for PPCs. 
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 Figure 7. MTT assay-determined IC50 values of complexes 3-6, 4ꞌ-6ꞌ, cisplatin and oxaliplatin in several human cancer 
cell lines, expressed on a logarithmic scale in nanomolar with standard error. Complexes 1, 2 and carboplatin were not 
included for clarity. 
4. Conclusions 
Three new platinum(II) derivatives of kiteplatin incorporating phen derivatives and 1,4-dach have 
been synthesised and characterised through several spectroscopic techniques. The CT-DNA binding 
of complexes 1-3 was assessed through ITC and compared to 1,2-dach analogues, revealing slightly 
higher DNA affinity for the former. The in vitro cytotoxicity of complexes 1-3 was found to be 
unexpectedly low in several human cell lines, with complex 3 demonstrating some results 
comparable with cisplatin. The results here indicate that the addition of 1,10-phenanthroline 
analogues to kiteplatin does not result in an improvement of anticancer activity and that DNA 
binding is not the primary mechanism of action of this type of complex. 
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Table 5.  Summary of the in vitro cytotoxicity of complexes 1-3 and 1ʹ-3ʹ in several cell lines, determined by the MTT assay and expressed as an IC50 value with standard error (1 sig. fig.). 
The activity of complexes 4-6 and 4ꞌ-6ꞌ, as well as that of cisplatin, oxaliplatin and carboplatin is also included. IC50 is the concentration at which cell growth is inhibited by 50% over 72 h. 
 IC50 (μM) 
Complex HT29a U87a MCF-7 A2780 H460 A431 Du145 BE2-C SJ-G2 MIA MCF10A 
1 PHENK 10 ± 1 >50 >50 25 ± 3 >50 >50 >50 46 ± 4 >50 >50 >50 
2 5KITE 2.1 ± 0.4 >50 14 ± 2 7 ± 1 >50 12 ± 2 43 ± 4 15.0 ± 0.3 30 ± 2 17 ± 2 50 ± 20 
3 56KITE 0.8 ± 0.1 47 ± 3 3.7 ± 0.6 2.9 ± 0.2 29 ± 5 4.4 ± 0.5 4.8 ± 0.7 5.7 ± 0.7 17 ± 2 4.0 ± 0.4 5 ± 1 
4 PHENSSa 0.13 ± 0.04 1.5 ± 0.4 0.5 ± 0.2 0.27 ± 0.03 0.5 ± 0.2 0.9 ± 0.3 0.08 ± 0.05 0.40 ± 0.05 0.45 ± 0.06 0.8 ± 0.7 0.16 ± 0.07 
4ꞌ PHENRRa 0.56 ± 0.08 8.9 ± 2.5 3.2 ± 0.2 2.70 ± 0.07 7.2 ± 0.9 2.0 ± 0.6 0.79 ± 0.08 3.8 ± 0.4 3.3 ± 0.3 2.7 ± 0.2 2.4 ± 0.3 
5 5MESS 0.02 ± 0.01 0.21 ± 0.04 0.08 ± 0.02 0.04 ± 0.01 0.07 ± 0.03  0.11 ± 0.04 0.02 ± 0.01 0.3 ± 0.1 0.15 ± 0.03 0.10 ± 0.07 0.03 ± 0.01 
5ꞌ 5MERR 0.19 ± 0.01 3.8 ± 0.4 1.3 ± 0.2 1.0 ± 0.2 2.8 ± 0.0 0.8 ± 0.2 1.3 ± 0.3 2.9 ± 0.2 2.9 ± 0.4 1.7 ± 0.2 1.6 ± 0.4 
6 56MESSa 0.08 ± 0.06 0.08 ± 0.01 0.05 ± 0.02 0.030 ± 0.004 0.037 ± 0.009  0.05 ± 0.02 0.007 ± 0.002 0.10 ± 0.02 0.07 ± 0.02 0.015 ± 0.002 0.020 ± 0.005 
6ꞌ 56MERRa 0.19 ± 0.00 2.2 ± 0.058 0.8 ± 0.1 1.1 ± 0.1 1.8 ± 0.2 0.93 ± 0.03 0.41 ± 0.04 2.3 ± 0.2 2.2 ± 0.2 0.45 ± 0.006 0.39 ± 0.01 
 Cisplatina 11 ± 2 4 ± 1 6.5 ± 0.8 1.0 ± 0.1 0.9 ± 0.2 2.4 ± 0.3 1.2 ± 0.1 1.9 ± 0.2 0.4 ± 0.1 8 ± 1 nd 
 Oxaliplatina 0.9 ± 0.2 1.8 ± 0.2 0.5 ± 0.1 0.16 ± 0.0 1.6 ± 0.1 4.1 ± 0.5 2.9 ± 0.4 0.9 ± 0.2 3 ± 1 0.9 ± 0.2 nd 
 Carboplatina >50 >50 >50 9 ± 3 14 ± 1 24 ± 2 15 ± 1 19 ± 1 5.7 ± 0.2 >50 nd 
a Reported in ref 21 and those within 
 
17 
 
Acknowledgments  
We thank Western Sydney University for providing financial support through internal research 
grants. B.J.P. was supported by an Australian Postgraduate Award and a Western Sydney 
University Top-Up Award. Crystallographic data collection was undertaken on the MX1 
beamline at Australian Synchrotron, Victoria, Australia. 
References 
1. Australian Institute of Health and Welfare and Australasian Association of Cancer 
Registries, Cancer in Australia 2017, Australian Institute of Health and Welfare, 
Canberra, 2017. 
2. Cancer Facts & Figures 2017, American Cancer Society, Atlanta, Georgia, 2017. 
3. N. J. Wheate, S. Walker, G. E. Craig and R. Oun, Dalton Trans., 2010, 39, 8113-8127. 
4. M. G. Apps, E. H. Y. Choi and N. J. Wheate, Endocr.-Relat. Cancer, 2015, 22, R219-
R233. 
5. B. H. Harper, F. Li, R. Beard, K. B. Garbutcheon-Singh, N. S. Ng and J. R. Aldrich-
Wright, in Supramolecular Systems in Biomedical Fields, ed. H. J. Schneider, Royal 
Society of Chemistry, Cambridge, UK, 1st edn., 2013, ch. 9. 
6. A.-M. Florea and D. Büsselberg, Cancers, 2011, 3, 1351-1371. 
7. J. D. Hoeschele, H. D. H. Showalter, A. J. Kraker, W. L. Elliott, B. J. Roberts and J. W. 
Kampf, J. Med. Chem., 1994, 37, 2630-2636. 
8. N. Margiotta, C. Marzano, V. Gandin, D. Osella, M. Ravera, E. Gabano, J. A. Platts, E. 
Petruzzella, J. D. Hoeschele and G. Natile, J. Med. Chem., 2012, 55, 7182-7192. 
9. J. Kasparkova, T. Suchankova, A. Halamikova, L. Zerzankova, O. Vrana, N. Margiotta, 
G. Natile and V. Brabec, Biochem. Pharmacol., 2010, 79, 552-564. 
10. V. Brabec, J. Malina, N. Margiotta, G. Natile and J. Kasparkova, Chem. Eur. J., 2012, 18, 
15439-15448. 
11. E. Petruzzella, N. Margiotta, G. Natile and J. D. Hoeschele, Dalton Trans., 2014, 43, 
12851-12859. 
12. N. Margiotta, E. Petruzzella, J. A. Platts, S. T. Mutter, R. J. Deeth, R. Ranaldo, P. 
Papadia, P. A. Marzilli, L. G. Marzilli, J. D. Hoeschele and G. Natile, Dalton Trans., 
2015, 44, 3544-3556. 
13. S. Mutter, N. Margiotta, P. Papadia and J. Platts, J. Biol. Inorg. Chem., 2015, 20, 35-48. 
14. J. Kasparkova, H. Kostrhunova, V. Novohradsky, J. Pracharova, A. Curci, N. Margiotta, 
G. Natile and V. Brabec, Dalton Trans., 2017, 46, 14139-14148. 
15. N. Margiotta, S. Savino, C. Marzano, C. Pacifico, J. D. Hoeschele, V. Gandin and G. 
Natile, J. Inorg. Biochem., 2016, 160, 85-93. 
16. N. Margiotta, S. Savino, N. Denora, C. Marzano, V. Laquintana, A. Cutrignelli, J. D. 
Hoeschele, V. Gandin and G. Natile, Dalton Trans., 2016, 45, 13070-13081. 
 18 
17. A. Curci, N. Denora, R. M. Iacobazzi, N. Ditaranto, J. D. Hoeschele, N. Margiotta and G. 
Natile, Inorg. Chim. Acta., 2017, In Press. 
18. S. Wang, V. Higgins, J. Aldrich-Wright and M. Wu, J. Chem. Biol., 2012, 5, 51-61. 
19. A. M. Krause-Heuer, R. Grünert, S. Kühne, M. Buczkowska, N. J. Wheate, D. D. Le 
Pevelen, L. R. Boag, D. M. Fisher, J. Kasparkova, J. Malina, P. J. Bednarski, V. Brabec 
and J. R. Aldrich-Wright, J. Med. Chem., 2009, 52, 5474-5484. 
20. K. B. Garbutcheon-Singh, S. Myers, B. W. J. Harper, N. S. Ng, Q. Dong, C. Xie and J. R. 
Aldrich-Wright, Metallomics, 2013, 5, 1061-1067. 
21. B. J. Pages, J. Sakoff, J. Gilbert, A. Rodger, N. P. Chmel, N. C. Jones, S. M. Kelly, D. L. 
Ang and J. R. Aldrich-Wright, Chem. Eur. J., 2016, 22, 8943-8954. 
22. R. Ranaldo, N. Margiotta, F. P. Intini, C. Pacifico and G. Natile, Inorg. Chem., 2008, 47, 
2820-2830. 
23. S. Kemp, N. J. Wheate, D. P. Buck, M. Nikac, J. G. Collins and J. R. Aldrich-Wright, J. 
Inorg. Biochem., 2007, 101, 1049-1058. 
24. T. M. McPhillips, S. E. McPhillips, H. J. Chiu, A. E. Cohen, A. M. Deacon, P. J. Ellis, E. 
Garman, A. Gonzalez, N. K. Sauter, R. P. Phizackerley, S. M. Soltis and P. Kuhn, J. 
Synchrotron Radiat., 2002, 9, 401-406. 
25. W. Kabsch, J. Appl. Crystallogr., 1993, 26, 795-800. 
26. SADABS: Empirical Absorption and Correction Software, University of Göttingen, 
1998. 
27. G. M. Sheldrick, Acta Crystallogr., Sect. C: Cryst. Struct. Commun., 2015, 71, 3-8. 
28. G. M. Sheldrick, SHELXT-2014, University of Göttingen, 2014. 
29. G. M. Sheldrick, SHELXL-2014, University of Göttingen, 2014. 
30. O. V. Dolomanov, L. J. Bourhis, R. J. Gildea, J. A. K. Howard and H. Puschmann, J. 
Appl. Crystallogr., 2009, 42, 339-341. 
31. B. J. Pages, J. Sakoff, J. Gilbert, Y. Zhang, F. Li, D. Preston, J. D. Crowley and J. R. 
Aldrich-Wright, J. Inorg. Biochem., 2016, 165, 92-99. 
32. B. J. Pages, F. Li, P. Wormell, D. L. Ang, J. K. Clegg, C. J. Kepert, L. K. Spare, S. 
Danchaiwijit and J. R. Aldrich-Wright, Dalton Trans., 2014, 43, 15566-15575. 
33. K. B. Garbutcheon-Singh, P. Leverett, S. Myers and J. R. Aldrich-Wright, Dalton Trans., 
2013, 42, 918-926. 
34. S. Kemp, N. J. Wheate, M. J. Pisani and J. R. Aldrich-Wright, J. Med. Chem., 2008, 51, 
2787-2794. 
35. B. M. Still, P. G. A. Kumar, J. R. Aldrich-Wright and W. S. Price, Chem. Soc. Rev., 
2007, 36, 665-686. 
36. A. R. Khokhar, S. Shamsuddin and Q. Xu, Inorg. Chim. Acta., 1994, 219, 193-197. 
37. L. M. Salonen, M. Ellermann and F. Diederich, Angew. Chem., Int. Ed., 2011, 50, 4808-
4842. 
38. B. N. Anila, N. M. K. Muraleedharan, J. Sreedharan and V. P. Sylas, Asian J. Chem., 
2017, 29, 691-702. 
39. S. Wang, M. J. Wu, V. J. Higgins and J. R. Aldrich-Wright, Metallomics, 2012, 4, 950-
959. 
 
 19 
